Skip Navigation

Link to  the National Institutes of Health  
The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse Archives of the National Institute on Drug Abuse web site
Go to the Home page
   
NIDA Home > NIDA Science & Practice Perspectives

NIDA Science & Practice Perspectives

Volume 2, Number 2 - August 2004

Reference Article Abstracts

Practical Considerations for the Clinical Use of Buprenorphine
[PDF - 284K]
Hendrée E. Jones, Ph.D.

Ahmadi, J., 2002. A controlled trial of buprenorphine treatment for opium dependence: The first experience from Iran. Drug and Alcohol Dependence 66(2):111-114. Abstract Available

Amass, L., et al., 1994. Alternate-day dosing during buprenorphine treatment of opiate dependence. Life Sciences 54(17):1215-1228. Abstract Available

Amass, L., et al., 1998. Alternate-day buprenorphine dosing is preferred to daily dosing by opiate-dependent humans. Psychopharmacology (Berlin) 136(3):217-225. Abstract Available

Amass, L.; Kamien, J.B.; and Mikulich, S.K., 2000. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug and Alcohol Dependence 58(1-2):143-152. Abstract Available

Amass, L.; Kamien, J.B.; and Mikulich, S.K., 2001. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug and Alcohol Dependence 61(2):173-181. Abstract Available

Barnett, P.G.; Zaric, G.S.; and Brandeau, M.L., 2001. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction 96(9):1267-1278. Abstract Available

Berson, A., et al., 2001a. Hepatitis after intravenous buprenorphine misuse in heroin addicts. Journal of Hepatology 34(2):346-350. Abstract Available

Berson, A., et al., 2001b. Mechanisms for experimental buprenorphine hepatotoxicity: Major role of mitochondrial dysfunction versus metabolic activation. Journal of Hepatology 34(2):261-269. Abstract Available

Bertschy, G., et al., 1996. Fluoxetine addition to methadone in addicts: Pharmacokinetic aspects. Therapeutic Drug Monitoring 18:570-572. Abstract Available

Bickel, W.K., et al., 1999. Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology (Berlin) 146(2):111-118. Abstract Available

Bouchez, J.; Beauverie, P.; and Touzeau, D., 1998. Substitution with buprenorphine in methadone- and morphine sulfate-dependent patients. European Addiction Research 4 (Suppl 1):8-12. Abstract Available

Carrieri, M.P., et al., 2000. Use of buprenorphine in HIV-infected injection drug users: Negligible impact on virologic response to HAART. The Manif-2000 Study Group. Drug and Alcohol Dependence 60(1):51-54. Abstract Available

de Castro, J., et al., 1996. The effect of changes in gastric pH induced by omeprazole on the absorption and respiratory depression of methadone. Biopharmaceutics Drug and Disposition 17(7):551-563. Abstract Available

Chiang, C.N., and Hawks, R.L., 2003. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug and Alcohol Dependence 70(Suppl): S39-S47. Abstract Available

Clarke, S., et al., 2002. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. Clinical Infectious Diseases 34(8):1143-1145. Abstract Available

Comer, S.D., and Collins, E.D., 2002. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. Journal of Pharmacology and Experimental Therapeutics 303(2):695-703. Abstract Available

Cowan, A.; Lewis, J.W.; and Macfarlane, I.R., 1977. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. British Journal of Pharmacology 60(4):537-545. Abstract Available

DeMaria, P.A., Jr., and Serota, R.D., 1999. A therapeutic use of the methadone fluvoxamine drug interaction. Journal of Addictive Disorders 18:5-12. Abstract Available

Eissenberg, T., et al., 1996. Buprenorphine’s physical dependence potential: Antagonist-precipitated withdrawal in humans. Journal of Pharmacology and Experimental Therapeutics 276(2):449-459. Abstract Available

Ernst, E., et al., 2002. Methadone-related deaths in Western Australia, 1993-1999. Australian and New Zealand Journal of Public Health 26:364-370. Abstract Available

Fhima, A., et al., 2001. Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex). Annales de Médecine Interne (Paris) 152(Suppl):26-36. Abstract Available

Fischer, G., et al., 1999. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 94(9):1337-1347. Abstract Available

Fudala, P.J., and Johnson, R.E., 1995. Clinical efficacy studies of buprenorphine for the treatment of opiate dependence. In: A. Cowan and J.W. Lewis (Eds.), Buprenorphine: Combatting Drug Abuse With a Unique Opioid. New York: Wiley-Liss, pp. 213-239.

Fudala, P.J., et al., 1990. Use of buprenorphine in the treatment of opioid addiction: II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clinical Pharmacology and Therapeutics 47(4):525-534. Abstract Available

Fudala, P.J., et al., 1998. Effects of buprenorphine and naloxone in morphine-stabilized opiate addicts. Drug and Alcohol Dependence 50(1):1-8. Abstract Available

Fudala, P.J., et al., 2003. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine 349 (Sept. 4):949-958. Abstract Available

George, T.P., et al., 2000. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: A preliminary trial. Biological Psychiatry 47(12): 1080-1086. Abstract Available

Gowing, L.; Ali, R.; and White, J., 2002. Buprenorphine for the management of opioid withdrawal. Cochrane Database of Systematic Reviews (2):CD002025. Abstract Available

Greenwald, M.K., et al., 2002. Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. Psychopharmacology (Berlin) 160(4):344-352. Abstract Available

Gross, A., et al., 2001. Limits to buprenorphine dosing: A comparison between quintuple and sextuple the maintenance dose every 5 days. Drug and Alcohol Dependence 64(1):111-116. Abstract Available

Harris, D.S., et al., 2000. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug and Alcohol Dependence 61(1):85-94. Abstract Available

Heelon, M.W., and Meade, L.B., 1999. Methadone withdrawal when starting an antiretroviral regimen including nevirapine. Pharmacotherapy 19(4):471-472. Abstract Available

Ibrahim, R.B., et al., 2000. Effect of buprenorphine on CYP3A activity in rat and human liver microsomes. Life Sciences 66(14):1293-1298. Abstract Available

Iribarne, C., et al., 1998. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metabolism Disposition 26(3):257-260. Abstract Available

Jasinski, D.R.; Pevnick, J.S.; and Griffith, J.D., 1978. Human pharmacology and abuse potential of the analgesic buprenorphine: A potential agent for treating narcotic addiction. Archives of General Psychiatry 35(4):501-516. Abstract Available

Johnson, R.E.; Jaffe, J.H.; and Fudala, P.J., 1992. A controlled trial of buprenorphine treatment for opioid dependence. Journal of the American Medical Association 267(20):2750-2755. Abstract Available

Johnson, R.E.; Jones, H.E.; and Fischer, G., 2003. Use of buprenorphine in pregnancy: Patient management and effects on the neonate. Drug and Alcohol Dependence 70 (2 Suppl.): S87-S101. Abstract Available

Johnson, R.E.; Strain, E.C.; and Amass, L., 2003. Buprenorphine: How to use it right. Drug and Alcohol Dependence 70(2 Suppl.):S59-S77. Abstract Available

Johnson, R.E., et al., 1989. Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction. Clinical Pharmacology and Therapeutics 46(3):335-343. Abstract Available

Johnson, R.E., et al., 1995a. A placebo-controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug and Alcohol Dependence 40(1):17-25. Abstract Available

Johnson, R.E., et al., 1995b. Buprenorphine treatment of opioid dependence: Clinical trial of daily versus alternate-day dosing. Drug and Alcohol Dependence 40(1):27-35. Abstract Available

Johnson, R.E., et al., 2000. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. New England Journal of Medicine 343(18):290-297. Abstract Available

Kakko, J., et al., 2003. One-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomized placebocontrolled trial. Lancet 361(9358):662-668. Abstract Available

Kaltenbach, K.; Berghella, V.; and Finnegan, L., 1998. Opioid dependence during pregnancy: Effects and management. Obstetrics and Gynecology Clinics of North America 25(1):139-151. Abstract Available

Kandall, S.R., et al., 1999. The methadone-maintained pregnancy. Clinics in Perinatology 26(1):173-183. Abstract Available

Kilicarslan, T., and Sellers, E.M., 2000. Lack of interaction of buprenorphine with flunitrazepam metabolism. American Journal of Psychiatry 157(7):1164-1166.

Kintz, P., 2002. Buprenorphine-related deaths. In P. Kintz and P. Marquet (Eds.), Buprenorphine Therapy of Opiate Addiction. Totowa, NJ: Humana Press, pp. 109-118. Abstract Available

Kosten, T.R., et al., 1990. Opiate antagonist challenges in buprenorphine-maintained patients. Drug and Alcohol Dependence 25(1):73-78. Abstract Available

Kosten, T.R., et al., 1992. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Archives of General Psychiatry 49(11):894-898. Abstract Available

Kosten, T.R., et al., 1993. Buprenorphine versus methadone maintenance for opioid dependence. Journal of Nervous and Mental Disease 181(6):358-364. Abstract Available

Kosten, T.R., et al., 2002. Ketoconazole increases cocaine and opioid use in methadone-maintained patients. Drug and Alcohol Dependence 66(2):173-180. Abstract Available

Kreek, M.J., 1981. Metabolic interactions between opiates and alcohol. Annals of the New York Academy of Sciences 362(1):36-49. Abstract Available

Krook, A.L., et al., 2002. A placebo-controlled study of high-dose buprenorphine in opiate-dependents waiting for medication-assisted rehabilitation in Olso, Norway. Addiction 97(5):533-542. Abstract Available

Kuhlman, J.J., Jr., et al., 1998. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction 93(4):549-559. Abstract Available

Lange, W.R., et al., 1990. Safety and side effects of buprenorphine in the clinical management of heroin addiction. Drug and Alcohol Dependence 26(1):19-28. Abstract Available

Leshner, A.I., 2003. Accessing opiate dependence treatment medications: Buprenorphine products in an office setting. Drug and Alcohol Dependence 70(2 Suppl.):S103-S104. Full Text Available

Levin, F.R., et al., 1997. A protocol to switch high-dose, methadone-maintained subjects to buprenorphine. American Journal on Addictions 6(2):105-116. Abstract Available

Lindhardt, K., et al., 2001. Intranasal bioavailability of buprenorphine in rabbit correlated to sheep and man. International Journal of Pharmaceutics 217(1-2):121-126. Full Text Available

Ling, W., and Smith, D., 2002. Buprenorphine: Blending practice and research. Journal of Substance Abuse Treatment 23(2):87-92. Abstract Available

Ling, W., et al., 1996. A controlled trial comparing buprenorphine and methadone maintenance in opiate dependence. Archives of General Psychiatry 53(5):401-407. Abstract Available

Ling, W., et al., 1998. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction 93(4):475-486. Abstract Available

Lintzeris, N., et al., 2002. Training primary health care professionals to provide buprenorphine and LAAM treatment. Substance Abuse 23(4):245-254. Abstract Available

Lintzeris, N., et al., 2003. Buprenorphine dosing regimen for inpatient heroin withdrawal: A symptom-triggered dose titration study. Drug and Alcohol Dependence 70(3):287-294. Abstract Available

Martin, W.R., et al., 1976. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. Journal of Pharmacology and Experimental Therapeutics 197(3):517-532. Abstract Available

Mattick, R.P., et al., 2003. Buprenorphine versus methadone maintenance therapy: A randomized double-blind trial with 405 opioid-dependent patients. Addiction 98(4):441-452. Abstract Available

McCance-Katz, E.F., et al., 1998. Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 18(5):435-443. Abstract Available

McCance-Katz, E.F., et al., 2003. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clinical Infectious Diseases 37(4):476-482. Abstract Available

Mello, N.K., and Mendelson, J.H., 1980. Buprenorphine suppresses heroin use by heroin addicts. Science 207(4431):657-659 Abstract Available.

Mendelson, J., and Jones, R.T., 2003. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: Why the 4:1 ratio for treatment? Drug and Alcohol Dependence 70(2 Suppl.):S29-S37. Abstract Available

Mendelson, J., et al., 1996. Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clinical Pharmacology and Therapeutics 60(1):105-114. Abstract Available

Mendelson, J., et al., 1997a. Bioavailability of sublingual buprenorphine. Journal of Clinical Pharmacology 37(1):31-37. Abstract Available

Mendelson, J., et al., 1997b. Buprenorphine and naloxone interactions in methadone maintenance patients. Biological Psychiatry 41(11):1095-1101. Abstract Available

Mendelson, J., et al., 1999. Buprenorphine and naloxone combinations: The effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology (Berlin) 141(1):37-46. Abstract Available

O’Brien, C.P., et al., 1978. Clinical pharmacology of narcotic antagonists. Annals of the New York Academy of Sciences 311(1):232-239. Abstract Available

O’Connor, P.G., 2000. Treating opioid dependence—new data and new opportunities. New England Journal of Medicine 343(18):1332-1334. Abstract Available

Oliveto, A., et al., 1995. Desipramine, amantadine, or fluoxetine in buprenorphine-maintained cocaine users. Journal of Substance Abuse Treatment 12(6):423-428. Full Text Available

Paetzold, W., et al., 2000. Detoxification of poly-substance abusers with buprenorphine: Effects on affect, anxiety, and withdrawal symptoms. Nervenarzt (Berlin) 71(9):722-729. Abstract Available

Pani, P.P., et al., 2000. Buprenorphine: A controlled clinical trial in the treatment of opioid dependence. Drug and Alcohol Dependence 60(1):39-50.

Perez de los Cobos, J.P., et al., 2000. A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence. Drug and Alcohol Dependence 59(3):223-233. Abstract Available

Petitjean, S., et al., 2001. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug and Alcohol Dependence 62(1):97-104. Abstract Available

Petry, N.M.; Bickel, W.K.; and Badger, G.J., 2000. A comparison of four buprenorphine dosing regimens using open-dosing procedures: Is twice-weekly dosing possible? Addiction 95(7):1069-1077. Abstract Available

Petry, N.M.; Bickel, W.K.; and Badger, G.J., 2001. Examining the limits of the buprenorphine interdosing interval: Daily, every-third-day and every-fifth-day dosing regimens. Addiction 96(6):823-834. Abstract Available

Petry, N.M., et al., 2000. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. American Journal on Addictions 9(3):265-269. Abstract Available

Pickworth, W.B., et al., 1993. Subjective and physiologic effects of intravenous buprenorphine in humans. Clinical Pharmacology and Therapeutics 53(5):570-576. Abstract Available

Preston, K.L.; Bigelow, G.E.; and Liebson, I.A., 1988. Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology (Berlin) 94(4):484-490. Abstract Available

Preston, K.L.; Bigelow, G.E.; and Liebson, I.A., 1990. Effects of sublingually given naloxone in opioid-dependent human volunteers. Drug and Alcohol Dependence 25(1):27-34. Abstract Available

Rainey, P.M., et al., 2002. The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. American Journal on Addictions 11(1):66-74. Abstract Available

Reynaud, M., et al., 1998. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 93(9):1385-1392. Abstract Available

Rosenheck, R., and Kosten, T., 2001. Buprenorphine for opiate addiction: Potential economic impact. Drug and Alcohol Dependence 63(3):253-262. Abstract Available

Rothman, R.B., et al., 2000. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence. Journal of Substance Abuse Treatment 18(3):277-281. Abstract Available

Schlatter, J., et al., 1999. Drug interactions with methadone. Presse Medicale (Paris) 28(25):1381-1384. Abstract Available

Schottenfeld, R.S.; Pakes, J.R.; and Kosten, T.R., 1998. Prognostic factors in buprenorphine- versus methadone-maintained patients. Journal of Nervous and Mental Disease 186(1):35-43. Abstract Available

Schottenfeld, R.S., et al., 1997. Buprenorphine versus methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Archives of General Psychiatry 54(8):713-720. Abstract Available

Schottenfeld, R.S., et al., 2000. Thrice-weekly versus daily buprenorphine maintenance. Biological Psychiatry 47(12):1072-1079. Abstract Available

Singh, R.A., et al., 1992. Cases of buprenorphine abuse in India. Acta Psychiatrica Scandinavica 86(1):46-48. Abstract Available

Stevens, R.C., et al., 2003. Lack of methadone dose alterations or withdrawal symptoms during therapy with lopinavir/ritonavir. Journal of Acquired Immune Deficiency Syndrome 33(5):650-651. Abstract Available

Stoller, K.B., et al., 2001. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berlin) 154(3):230-242.

Strain, E.C. (Ed.), 2001. Use of Buprenorphine in the Pharmacologic Management of Opioid Dependence: A Curriculum for Physicians. http://buprenorphine.samhsa.gov. January 30, 2003. Full Text Available [pdf]

Strain, E.C., et al., 1992. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. Journal of Pharmacology and Experimental Therapeutics 261(3):985-993. Abstract Available

Strain, E.C., et al., 1993. Precipitated withdrawal by pentazocine in methadone-maintained volunteers. Journal of Pharmacology and Experimental Therapeutics 267(2):624-634. Abstract Available

Strain, E.C., et al., 1994. Comparison of buprenorphine and methadone in the treatment of opioid dependence. American Journal of Psychiatry 151(7):1025-1030. Abstract Available

Strain, E.C., et al., 1995. Buprenorphine effects in methadone-maintained volunteers: Effects at two hours after methadone. Journal of Pharmacology and Experimental Therapeutics 272(2):628-638. Abstract Available

Strain, E.C., et al., 1997. The effects of buprenorphine in buprenorphine-maintained volunteers. Psychopharmacology (Berlin) 129(4):329-338. Abstract Available

Strain, E.C., et al., 2000. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacology (Berlin) 148(4):374-383. Abstract Available

Substance Abuse and Mental Health Services Administration, 2002. National Survey on Drug Use and Health (NSDUH), 2002. Abstract Available

Substance Abuse and Mental Health Services Administration, 2003. http://buprenorphine.samhsa.gov, February 12, 2003.

Tong, T.G.; Benowitz, N.L.; and Kreek, M.J., 1980. Methadone-disulfiram interaction during methadone maintenance. Journal of Clinical Pharmacology 20(8):506-513. Abstract Available

Uehlinger, C., et al., 1998. Comparison of buprenorphine and methadone in the treatment of opioid dependence. European Addiction Research 4(Suppl 1):13-18. Abstract Available

U.S. Food and Drug Administration, 2003. Product Discontinuation Notice: ORLAAM. www.fda.gov/cder/drug/shortages/orlaam.htm, August 23.

Varescon, I., et al., 2002. Buprenorphine abuse: High dose intravenous administration of buprenorphine [French]. L’Encephale 28(5 Pt. 1):397-402. Abstract Available

Vastag, B., 2003. In-office opiate treatment “not a panacea”: Physicians slow to embrace therapeutic option. Journal of the American Medical Association 290(6):731-735. Abstract Available

Walsh, S.L., et al., 1994. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clinical Pharmacology and Therapeutics 55(5):569-580. Abstract Available

Walsh, S.L., et al., 1995. Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology (Berlin) 119(3):268-276. Abstract Available

Wang, E.C., 1999. Methadone treatment during pregnancy. Journal of Obstetric, Gynecologic, and Neonatal Nursing 28(6):615-622. Abstract Available

White, J.M., and Irvine, R.J., 1999. Mechanisms of fatal opioid overdose. Addiction 94(7):961-972. Abstract Available

Woody, G.E., 2003. Buprenorphine/Naloxone-Facilitated Rehabilitation for Opioid-Dependent Adolescents/Young Adults. CTN protocol NIDA-CTN-0010, October 31, 2003.

Behavioral Couples Therapy for Substance Abuse: Rationale, Methods, and Findings
[PDF - 252K]
William Fals-Stewart, Ph.D., Timothy J. O’Farrell, Ph.D., and Gary R. Birchler, Ph.D.

Fals-Stewart, W., 2003. The occurrence of interpartner physical aggression on days of alcohol consumption: A longitudinal diary study. Journal of Consulting and Clinical Psychology 71(1):41-52. Abstract Available

Fals-Stewart, W., and Birchler, G.R., 2001. A national survey of the use of couples therapy in substance abuse treatment. Journal of Substance Abuse Treatment 20(4):277-283, discussion 285-286. Abstract Available

Fals-Stewart, W.; Birchler, G.R.; and O’Farrell, T.J., 1996. Behavioral couples therapy for male substance-abusing patients: Effects on relationship adjustment and drug-using behavior. Journal of Consulting and Clinical Psychology 64(5):959-972. Abstract Available

Fals-Stewart, W.; Birchler, G.R.; and O’Farrell, T.J., 1999. Drug-abusing patients and their intimate partners: Dyadic adjustment, relationship stability, and substance use. Journal of Abnormal Psychology 108(1):11-23. Abstract Available

Fals-Stewart, W.; Golden, J.; and, Schumacher, J., 2003. Intimate partner violence and substance use: A longitudinal day-to-day examination. Addictive Behaviors 28(9):1555-1574. Abstract Available

Fals-Stewart, W., and O’Farrell, T.J., 2003. Behavioral family counseling and naltrexone compliance for male opioid-dependent patients. Journal of Consulting and Clinical Psychology 71(3):432-442. Abstract Available

Fals-Stewart, W.; O’Farrell, T.J.; and Birchler, G.R., 1997. Behavioral couples therapy for male substance-abusing patients: A cost-outcomes analysis. Journal of Consulting and Clinical Psychology 65(5):789-802. Abstract Available

Fals-Stewart, W., et al., 2002. Behavioral couples therapy for drug-abusing patients: Effects on partner violence. Journal of Substance Abuse Treatment 22(2):87-96. Abstract Available

Kelley, M.L., and Fals-Stewart, W., 2002. Couples- versus individual-based therapy for alcoholism and drug abuse: Effects on children’s psychosocial functioning. Journal of Consulting and Clinical Psychology 70(2):417-427. Abstract Available

Maisto, S.A., et al., 1988. Alcoholics’ attributions of factors affecting their relapse to drinking and reasons for terminating relapse episodes. Addictive Behaviors 13(1):79-82. Abstract Available

McCrady, B., et al., 1991. Effectiveness of three types of spouse-involved alcoholism treatment. British Journal of Addiction 86(11):1415-1424. Abstract Available

O’Farrell, T.J., and Fals-Stewart, W., 2003. Alcohol abuse. Journal of Marital and Family Therapy 29(1):121-146. Abstract Available

O’Farrell, T.J., et al., 1993. Behavioral marital therapy with and without additional couples relapse prevention sessions for alcoholics and their wives. Journal of Studies on Alcohol 54(6):652-666. Abstract Available

O’Farrell, T.J., et al., 2003. Partner violence before and after individually based alcoholism treatment for male alcoholic patients. Journal of Consulting and Clinical Psychology 71(1):92-102. Abstract Available

Stanton, M.D., and Shadish, W.R., 1997. Outcome, attrition, and family-couples treatment for drug abuse: A meta-analysis and review of the controlled, comparative studies. Psychological Bulletin 122(2):170-191. Abstract Available

Winters, J., et al., 2002. Behavioral couples therapy for female substance-abusing patients: Effects on substance use and relationship adjustment. Journal of Consulting and Clinical Psychology 70(2):344-355. Abstract Available

Residential Treatment for Parents and Their Children: The Village Experience
[PDF - 276K]
Valera Jackson, M.S.

Grella, C.E., 1996. Background and overview of mental health and substance abuse treatment systems: Meeting the needs of women who are pregnant and parenting. Journal of Psychoactive Drugs 28(4):319-343. Abstract Available

Hawkins, J.D.; Catalano, R.F.; and Miller, J.Y., 1992. Risk and protective factors for alcohol and other drug problems in adolescence and early adulthood: Implications for substance abuse prevention. Psychological Bulletin 112(1):64-105. Abstract Available

Johnson, B.D.; Dunlap, E.; and Maher, L., 1998. Nurturing for careers in drug use and crime: Conduct norms for children and juveniles in crack-using households. Substance Abuse & Misuse 33(7):1511-1546. Abstract Available

Liddle, H.A., et al., 2001. Multidimensional family therapy for adolescent drug abuse: Results of a randomized clinical trial. American Journal of Drug and Alcohol Abuse 27(4):651-688. Abstract Available

Metsch, L., et al., 1995. Implementation of a family-centered treatment program for substance-abusing women and their children: Barriers and resolutions. Journal of Psychoactive Drugs 27(1):73-83. Abstract Available

Nelson-Zlupko, L., et al., 1996. Women in recovery: Their perceptions of treatment effectiveness. Journal of Substance Abuse Treatment 13(1):51-59. Abstract Available

Substance Abuse and Mental Health Services Administration (SAMHSA), 2002. Characteristics and needs of the population: Understanding co-occurring disorders. In Report to Congress on the Prevention and Treatment of Co-Occurring Substance Abuse Disorders and Mental Disorders, 2002. http://www.samhsa.gov/reports/congress2002/index.html.



- Current Issue Index
- Subscribe to the Journal

Get Adobe Reader



NIDA Addiction Science & Clinical Practice
Subscription Department
RTI International
1375 Piccard Drive, Suite 175
Rockville, MD 20850

Fax: (240) 632–0519

Email: nida-ascp@masimax.com



Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page
National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. . The U.S. government's official web portal